A
SUPN icon

Argentarii’s Supernus Pharmaceuticals SUPN Stock Holding History

Argentarii’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$388K Hold
7,500
– – 0.14% 136
2025
Q4 		$373K Hold
7,500
– – 0.12% 139
2025
Q3 		$358K Hold
7,500
– – 0.14% 112
2025
Q2 		$236K Hold
7,500
– – 0.11% 139
2025
Q1 		$246K Hold
7,500
– – 0.12% 138
2024
Q4 		$271K Buy
+7,500
New +$264K 0.14% 125

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Argentarii's SUPN Position: Q1 2026 in Review

Argentarii held its Supernus Pharmaceuticals (SUPN) position steady in Q1 2026 at 7,500 shares worth $388K. The position accounts for 0.14% of the portfolio, ranked #136.

Argentarii first reported a position in SUPN in Q4 2024 and has held it in 6 quarters since. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Argentarii held 7,500 shares of Supernus Pharmaceuticals worth $388K as of Q1 2026.
  • Argentarii left its Supernus Pharmaceuticals share count unchanged in Q1 2026.
  • Supernus Pharmaceuticals made up 0.14% of Argentarii's portfolio in Q1 2026, its #136 holding.
  • Argentarii first reported a position in Supernus Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Argentarii's 13F filing for Q1 2026, filed 12 May 2026.